Travere Therapeutics' Depreciation & Amortization (CF) rose 40.48% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.7 million, marking a year-over-year increase of 33.56%. This contributed to the annual value of $43.6 million for FY2024, which is 13.04% up from last year.
According to the latest figures from Q3 2025, Travere Therapeutics' Depreciation & Amortization (CF) is $15.8 million, which was up 12.64% from $14.0 million recorded in Q2 2025.
In the past 5 years, Travere Therapeutics' Depreciation & Amortization (CF) ranged from a high of $15.8 million in Q3 2025 and a low of -$7.8 million during Q4 2021.
Moreover, its 3-year median value for Depreciation & Amortization (CF) was $11.2 million (2024), whereas its average is $11.3 million.
Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first tumbled by 217.91% in 2021, then surged by 1,547.04% in 2023.
Travere Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at -$7.8 million in 2021, then soared by 180.71% to $6.3 million in 2022, then surged by 50.32% to $9.5 million in 2023, then increased by 27.43% to $12.1 million in 2024, then surged by 40.48% to $15.8 million in 2025.
Its last three reported values are $15.8 million in Q3 2025, $14.0 million for Q2 2025, and $12.8 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value